Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
Ewa Fiorentino-Rozek, Head of Clinical Affairs at AliveDx, shared a post on LinkedIn:
“IVD of the Week: Blood Group Genotyping – Are We Ready for Routine Use?
Blood group genotyping has come a long way in recent years. It started as a specialized tool for identifying rare donors and solving complex antibody cases, but it’s increasingly being talked about as part of routine blood bank practice.
Compared to traditional serology, genotyping can:
– Detect blood group variants that serology can miss
– Improve matching for patients who receive frequent transfusions (like those with sickle cell disease or thalassemia
– Help manage rare donor inventories more effectively
Yet despite all this progress, many labs still rely mostly on serological methods. Making genotyping a routine part of blood banking isn’t simple. There are real hurdles:
– Cost – both for instruments and ongoing reagents
– Integration – adapting workflows and training staff
– Data interpretation – translating genotyping results into clear transfusion decisions
– Guidelines – not all regions have clear recommendations on when or how to implement routine genotyping
I’d love to hear from colleagues across labs, blood services, and industry:
– Is your center already using genotyping routinely, or only for special cases?
– What barriers are slowing down broader adoption where you work?
– Do you think genotyping will become standard practice in the next five years—or is that still further off?
Let’s share real-world experiences and thoughts on how to bridge the gap between promise and practice in blood group genotyping.
________
Hi, I’m Ewa, and I help In Vitro Diagnostics companies bring innovative products to market.
Follow me for insights on IVD regulations, performance evaluation, and industry trends.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week